FOI release

Vaxrevia vaccination - embolism, thrombosis and decreased platelet count

This request was refused in full, so we didn't provide the information the requester asked for. This may include information where we can neither confirm nor deny that we hold it.

Case reference FOI2026/00052

Received 19 January 2026

Published 5 May 2026

Request

Dear Medicines and Healthcare Products Regulatory Agency, would you please provide me with all reports in which there was one event (MedDRA PT) from the Embolism and thrombosis HGLT (Vascular disorders SOC) and the PT of thrombocytopenia (Blood and lymphatic system disorders SOC) OR the PT of platelet count decreased (investigations SOC) OR platelet count abnormal (Investigations SOC). To be clear this request relates to event reports following exposure to Covid-19 AstraZeneca Vaccine (AZD1222/ChAdOx1-S) Vaxrevia - during the period of its licensing (2021-2024).

Response

See attached

Documents

• FOI2026_00052 (redacted).pdf (859.9 KB)

This is Medicines and Healthcare products Regulatory Agency's response to a freedom of information (FOI) or environmental information regulations (EIR) request.

You can browse our other responses or make a new FOI request.